perimental diabetes has been empirically but not mechanistically linked to altered nerve myo-inositol metabolism. The phospholipid-dependent membranebound sodium-potassium ATPase provides a potential mechanism to relate defects in diabetic peripheral nerve myo-inositol-phospholipid metabolism, impulse conduction, and energy utilization. Therefore, the effect of streptozocin-induced diabetes mellitus and dietary myo-inositol supplementation on rat sciatic nerve sodium-potassium ATPase was studied. ATPase activity was measured enzymatically in sciatic nerve homogenates from 4-wk streptozocin diabetic rats and age-matched controls either fed a standard or 1% myoinositol supplemented diet. The sodium-potassium ATPase components were assessed by ouabain inhibition or the omission of sodium and potassium ions. Diabetes reduced the composite ATPase activity recovered in crude homogenates of sciatic nerve. The 40% reduction in the sodium-potassium ATPase was selectively prevented by 1% myo-inositol supplementation (which preserved normal nerve conduction). Thus, in diabetic peripheral nerve, abnormal myo-inositol metabolism is associated with abnormal sodiumpotassium ATPase activity. The mechanism of the effect of dietary myo-inositol to correct diabetic nerve conduction may be through changes in a sodium-potassium ATPase, possibly via changes in myo-inositolcontaining phospholipids.
INTRODUCTION
Nerve conduction is impaired in overt diabetic neuropathy by a combination of structural and metabolic A preliminary report of this work was presented at the National Meeting of the American Federation of Clinical Research in Wash. DC, April 1983. Received for publication 15 March 1983 and in revised form 13 May 1983. defects in peripheral nerve (1, 2) . Furthermore, the histologically demonstrable axonal degeneration and segmental demyelination are thought to reflect longstanding metabolic derangements in diabetic peripheral nerve Schwann cells and/or axons (2) . These unknown metabolic abnormalities alone presumably explain the acute and rapidly reversible conduction impairment in newly diagnosed human diabetes (2) .
Nerve conduction defects in acutely diabetic animals resemble the metabolically mediated conduction impairment in human diabetics (3) (4) (5) (6) . In the acute streptozocin diabetic rat, where diabetic nerve metabolism and function are readily compared, impaired nerve conduction has been linked to an alteration in peripheral nerve myo-inositol (MI)' metabolism (3, 7, 8) that results from insulin deficiency and/or hyperglycemia (3) (an analogous alteration in MI metabolism was recently demonstrated in human diabetic nerve [9] ). In vitro studies with rabbit peripheral nerve suggest that competitive inhibition of sodium-dependent MI uptake by hyperglycemic glucose concentrations may contribute to this fall in diabetic nerve MI content (10) , as may increased polyol-pathway metabolism (8, 11, 12) .
The relationship between altered MI metabolism and impaired nerve function is poorly understood. Recent single-node voltage-clamp studies in peripheral nerve from the spontaneously-diabetic BB rat ascribe impaired nerve conduction to a reduction in the resting axonal transmembrane sodium potential, possibly attributable to reduced sodium-pump activity (13) . The sodium-potassium ATPase, which generates the transmembrane sodium gradient in peripheral nerve, consumes the major fraction of the tissue's energy flux (14) . Impaired resting energy utilization is a prominent metabolic defect in diabetic peripheral nerve (15) . Furthermore, Das et al. (16) documented a reduction in sciatic nerve sodium-potassium ATPase activity in chronic streptozocin diabetic rats, but did not explore its possible metabolic relationships to insulin deficiency or hyperglycemia. Since conduction impairment in the acutely streptozocin diabetic rat is corrected by normalization of peripheral nerve MI metabolism (3, 7, 8) , and since endogenous MI-containing phospholipids may modulate sodium-potassium ATPase in some tissues (17) , we hypothesized that abnormal MI metabolism might underlie a sodium-potassium ATPase defect in diabetic peripheral nerve (18) . This line of speculation was previously suggested by Clements (2), and may be strengthened by the recent observation that peripheral nerve free MI levels influence the metabolism of MI-containing phospholipids (19) .
Therefore, we measured sodium-potassium-activated and ouabain-inhibited ATPase enzymatically in sciatic nerve homogenates from normal and streptozocin diabetic rats fed either normal or MI-supplemented diets (3, 7) . Acute streptozocin-induced diabetes produced a 40% reduction in sodium-potassiumactivated and ouabain-inhibited ATPase activity. This defect was selectively and completely prevented by the dietary 1% MI administration that normalizes nerve MI content and conduction velocity in streptozocin diabetic rats (3, 7). Plasma and sciatic nerve MI were determined by gas-liquid chromatography in protein-free Somogyi filtrates of cardiac blood plasma or sciatic nerve homogenates as previously described (3) and expressed per milliliter of plasma or per gram wet weight of whole nerve (3, 7) . The determinations of MI were performed on trimethylsilyl derivatives of lyophilized aliquots of the plasma or nerve filtrates containing alpha-D-methyl mannopyranoside as an internal standard in a Varian 3700 gas-liquid chromatograph on a 6 ft X 4 mm 3% SE-30 Gaschrom Q glass column at 185°C with a nitrogen carrier-gas flow rate of 40 ml/min using a flame ionization detector maintained at 250°C. Standard curves were determined daily, and the recovery of added MI to nerve or plasma samples consistently exceeded 95%.
METHODS
Sodium-potassium activated and ouabain-inhibited ATPase activity was measured in freshly prepared crude homogenates of whole sciatic nerve and expressed per gram wet weight or milligram Lowry protein (21) . Fresh sciatic nerve segments were minced and homogenized at 40°C in 2 ml of 0.2 M sucrose-0.02 M Tris-HCI buffer solution pH 7.5, using a Polytron homogenizer (model , Brinkman Instruments, Inc, Westbury, NY), for at least three periods, not exceeding 15 s each (16) and centrifuged at 100 g for 2 min at 4°C. 5-20 Ml of supernatant was added to 1.0 ml X 1.0 cm disposable cuvettes (Fisher Scientific, Pittsburgh, PA) containing (final concentration) 100 mM NaCl, 10 mM KCI, 2.5 mM MgCl2, 1 mM Tris-ATP, 1 mM tri(cyclohexylammonium) phosphoenolpyruvate, 30 mM imidazole-HCl buffer (pH 7.3), 0.15 mM NADH, and 50 Mg of lactate dehydrogenase and 30 Mg of pyruvate kinase (22) .
After initial stabilization, the oxidation of NADH was monitored at 340 nm in a Cary 210 Spectrophotometer in the dual-beam mode, and was linear with respect to time for at least 45 min. Sodium-potassium-activated ATPase activity was computed by subtracting (a) the reaction rate in an identical cuvette from which NaCl and KCI were omitted from (b) the reaction rate in the cuvette containing both of these salts (preliminary studies indicated that identical results were obtained if sodium alone were omitted). Ouabaininhibited ATPase activity was measured by comparing the reaction rate before and after the addition of 0.10 mM ouabain (final concentration). (Preliminary experiments indicated that the final reaction rate was identical in cuvettes in which ouabain was added initially or after an initial linear rate was obtained in the absence of ouabain. Furthermore, 0.1 mM ouabain produced maximal inhibition within the concentration range of 0.05-1.0 mM ouabain.) The addition of ouabain had no effect on the apparent rate of the reaction in the absence of both sodium and potassium ions. Both ouabain-inhibited and sodium-potassium-stimulated activities were linear with time for at least 45 (20) in sciatic nerve crude homogenates from normal and 4-wk streptozocin diabetic rats fed either a standard or 1% MI supplemented diet. Ouabain-inhibited ATPase activity denotes the differential rate of ADP generated upon addition of 0.10 mM ouabain to the reaction mixture; non-ouabain-inhibited ATPase activity denotes residual ADP generation in the presence of ouabain. Sodium-potassium-stimulated ATPase activity indicates the differential rate of ADP generation when sodium and potassium ions are omitted from the reaction mixture. Values are mean±SEM, and P values are computed with the student's twotailed t test (21) .
in the absence of dietary MI supplementation; and the 1% MI diet raised diabetic sodium-potassium-stimulated ATPase activity by 58%, so that it no longer differed significantly from the nondiabetic in either dietary group. Thus, both ouabain inhibition and sodium-potassium stimulation appeared to define the same ATPase activity in sciatic nerve homogenates, i.e., the sodium-potassium ATPase. Nonouabain-inhibited ATPase activity (column 4). Nonouabain-inhibited ATPase activity (i.e., residual activity in the presence of inhibitory concentrations of ouabain) was significantly lowered by experimental diabetes, but was unaffected by dietary MI in either diabetic or nondiabetic nerve. Similar results were obtained in the non-sodium-potassium-stimulated component (Fig. 1) (10) and/or increased polyol pathway activity (8, 11, 12) . Thus, the sodiumpotassium ATPase abnormality in diabetic peripheral nerve is an indirect consequence of insulin deficiency and/or its consequent hyperglycemia. The sodium-potassium ATPase plays a central role in both nerve metabolism and function (24) ; accordingly, its 40% reduction in diabetes, if expressed in vivo, would appear to have important pathophysiological implications in experimental diabetic neuropathy. First, nerve conduction slowing in the spontaneously-diabetic BB rat has been attributed to a reduction in the resting transaxolemmal sodium electrochemical gradient (13) generated by the sodium-potassium ATPase (14) . Second, nerve conduction slowing in the streptozocin diabetic rat is prevented by dietary MI administration (3), which normalizes nerve sodium-potassium ATPase activity. Thus, the conduction impairment in diabetic rat sciatic nerve and its correction by 1% dietary MI are probably both mediated by changes in sodium-potassium ATPase activity (18) . (Peripheral nerve is a heterogeneous tissue comprised of axons, Schwann cells, the perineurial epithelium, and endo-and epineurial connective, vascular and adipose tissue, all of which may possess sodium-potassium ATPase activity. However, the electrophysiological observations cited above suggest that variation in whole-nerve homogenate sodium-potassium ATPase activity parallels that of the cellular elements responsible for nerve impulse conduction in vivo.) The mechanism(s) relating intracellular free MI and sodium-potassium ATPase function are unclear. The strikingly high intracellular MI concentration characteristic of many mammalian cell lines has no welldefined biological role, although its major metabolic activity is reversible incorporation into membrane phosphoinositide (2, 25) . Since tissue MI levels influence nondiabetic peripheral nerve phosphoinositide turnover (19) , abnormalities in diabetic peripheral nerve phosphoinositide metabolism (26-28) may reflect altered tissue free MI levels (2). Since membrane phosphatidylinositol is an endogenous activator of renal microsomal sodium potassium ATPase in the rat (29) , it is tempting to speculate that altered membrane phosphatidylinositol composition or metabolism underlies the sodium-potassium ATPase defect in diabetic rat peripheral nerve. The preservation of the sodium-potassium ATPase defect in cell-free homogenates of diabetic rat sciatic nerve is consistent with either a numerical reduction or compositional alteration in the sodium-potassium ATPase-membrane complex, the latter involving either the ATPase protein subunits themselves, their attached oligosaccharide residues, tightly-bound regulatory ligands, or the surrounding membrane lipid and protein milieu (30) . Detailed metabolic and compositional studies in diabetic peripheral nerve are necessary to fully clarify the relationship(s) between nerve sodium-potassium ATPase activity and MI metabolism.
In summary. acute streptozocin diabetes reduces sciatic nerve MI concentration (3, 7, 8, 26, 27) , conduction velocity (3, 6, 7) and sodium-potassium ATPase activity. MI administration obviates the fall in tissue MI and prevents the decrease in both nerve conduction velocity (3, 7, 8) and sodium-potassium ATPase. Since conduction impairment in experimental diabetes is attributable to a reduction in the ATPase-generated (14) sodium gradient (13) , the ameliorative effect of MI administration on diabetic nerve conduction is likely mediated via a sodium-potassium ATPase effect. Because peripheral nerve sodium-potassium ATPase is fundamental to both energy (14) and substrate (31) metabolism, MI-related sodium-potassium ATPase perturbations might have widespread consequences in diabetic nerve (a recent report attributes the impaired "slow axonal transport" implicated in the "distal axonopathy" of diabetes [32] , to altered diabetic rat nerve MI metabolism, since it is corrected by MI administration [8] ). Finally, since nerve MI uptake is a sodium-gradient-dependent process (10), impaired sodium-potassium ATPase activity plus the competitive inhibition of sodium-dependent MI uptake by glucose (10) may synergistically blunt MI uptake by forming a self-reinforcing cycle of progressively reduced MI uptake, altered MI metabolism, and impaired sodium-potassium ATPase function leading to widespread functional and possible structural alterations in diabetic peripheral nerve (18) .
